Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine

NCT00085293 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00085293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00085293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2004
Completion date
May 31, 2014
Enrollment
12 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent thyroid cancer, stage iva follicular thyroid cancer, stage iva papillary thyroid cancer, stage ivb follicular thyroid cancer, stage ivb papillary thyroid cancer, stage ivc follicular thyroid cancer, stage ivc papillary thyroid cancer